$Predictive Oncology (POAI.US)$ NEWS 04/30/24 Predictive Onc...
NEWS 04/30/24
Predictive Oncology Announces Progress With FluGen In the Development Of First-Of-Its-Kind Intranasal Flu Vaccine, As Part Of A $6.2M Phase 2B Grant Awarded By The U.S. DOD
Benzinga
04/30/2024 16:44
Follow
Here's a summary of this article.
Predictive Oncology Inc. Announces a collaboration with FluGen to bring a first-of-its-kind intranasal flu vaccine to market. The project is part of a $6.2 million grant awarded by the U.S. Department of Defense. Predictive oncology will help FluGen develop a stable and stable vaccine.
Warning: Information on this page was generated through the use of artificial intelligence (“AI”). Read More
POAI
+5.
Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery and biologics, announces a collaboration with FluGen to bring a first-of-its-kind intranasal flu vaccine to market, as part of a $6.2 million Phase 2B grant awarded by the United States Department of Defense (DoD). "Predictive Oncology will play a critical role in helping to make our M2SR flu vaccine more stable and sustainable as we advance our clinical trials," says Paul Radspinner, President & Chief Executive Officer of FluGen. "The project looks to hold tremendous promise."
Through a proprietary design of experiments, the Predictive Oncology biologics team will be developing a formulation that is soluble and stable in a refrigerated state, which is a vital part in the drug development process. Most importantly, this addresses the need for a longer vaccine shelf-life to support global distribution including remote locations. Predictive Oncology's biologics capabilities are uniquely suited to help achieve maximum stability, one of the initial critical milestones.
"We are excited to advance these efforts for an intranasal flu vaccine that will be unlike any other on the market," notes Larry DeLucas, Senior Vice President of Biologics at Predictive Oncology. "Utilizing our exceptional technology and supported by our team of leading scientists, this work will allow FluGen to continue its clinical trials with greater potential to bring a more advanced and stable flu vaccine to patients."
Benzinga
04/30/2024 16:44
Follow
Here's a summary of this article.
Predictive Oncology Inc. Announces a collaboration with FluGen to bring a first-of-its-kind intranasal flu vaccine to market. The project is part of a $6.2 million grant awarded by the U.S. Department of Defense. Predictive oncology will help FluGen develop a stable and stable vaccine.
Warning: Information on this page was generated through the use of artificial intelligence (“AI”). Read More
POAI
+5.
Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery and biologics, announces a collaboration with FluGen to bring a first-of-its-kind intranasal flu vaccine to market, as part of a $6.2 million Phase 2B grant awarded by the United States Department of Defense (DoD). "Predictive Oncology will play a critical role in helping to make our M2SR flu vaccine more stable and sustainable as we advance our clinical trials," says Paul Radspinner, President & Chief Executive Officer of FluGen. "The project looks to hold tremendous promise."
Through a proprietary design of experiments, the Predictive Oncology biologics team will be developing a formulation that is soluble and stable in a refrigerated state, which is a vital part in the drug development process. Most importantly, this addresses the need for a longer vaccine shelf-life to support global distribution including remote locations. Predictive Oncology's biologics capabilities are uniquely suited to help achieve maximum stability, one of the initial critical milestones.
"We are excited to advance these efforts for an intranasal flu vaccine that will be unlike any other on the market," notes Larry DeLucas, Senior Vice President of Biologics at Predictive Oncology. "Utilizing our exceptional technology and supported by our team of leading scientists, this work will allow FluGen to continue its clinical trials with greater potential to bring a more advanced and stable flu vaccine to patients."
- TTSAB
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
613Followers
73Following
3961Visitors
Follow
Sean Parker : Am i the only one that finds it very weird that the DOD is funding this... Dont we have a government department thats for health? All i know is I'm not taking it lol.